Needham Reiterates Buy Rating on Alkermes plc
Needham maintains its buy rating on Alkermes plc with a $54 price target, a 12.10% upside from the current price.
Key Points
- Needham reiterated its buy rating on Alkermes plc, setting a price target of $54 on June 18, 2026.
- Needham's $54 price target implies 12.10% upside from Alkermes plc's ($ALKS) current $48.17 share price.
- Shares of Alkermes (NasdaqGS: ALKS) are trading near $45.1, with a market cap of approximately $7.42 billion.
- Several insiders have recently sold shares, including EVP Craig Hopkinson, who sold 9,000 shares at $41.67.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On June 18, 2026, Needham reiterated its buy rating on Alkermes plc, a pharmaceutical company listed on NasdaqGS under the ticker ALKS. Analyst Ami Fadia set a price target of $54 for the stock, which is currently trading around $45.1.
Alkermes plc Stock Up 1.6%
Shares of Alkermes (NasdaqGS: ALKS) are trading near $45.1. The company has a market cap of about $7.42 billion and a P/E ratio of 49.46. Its forward P/E ratio is 18.90, indicating future earnings expectations. With a beta of 0.334, Alkermes is less volatile compared to the market. The stock has traded between $25.17 and $45.76 over the last 52 weeks, with a 50-day moving average of $37.64 and a 200-day moving average of $32.10.
$ALKS price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Recent Earnings
Alkermes reported revenue of approximately $1.56 billion, reflecting a growth rate of 28.2%. The company has a net margin of 9.78% and a return on equity of 9.36%. The next earnings report is expected on July 28, 2026.
Insider Buying and Selling at Alkermes plc
Recent insider transactions at Alkermes include several planned sales. On June 12, 2026, Christopher Wright sold 2,000 shares at an average price of $45.1. Earlier, on June 4, David Joseph Gaffin, EVP and CLO, sold 2,034 shares at $43.05. Craig Hopkinson, EVP of R&D and Chief Medical Officer, sold 9,000 shares at $41.67 on June 1 under a planned sale, though he also purchased 5,000 shares on the same day without a plan.
Analysts Set New Price Targets
On June 18, 2026, Needham maintained its buy rating for Alkermes with a price target of $54. Other firms such as RBC Capital and Baird have also maintained buy ratings with targets at $56 and $48, respectively. The overall analyst consensus is a buy, with a mean target price of $46.13 from 16 analysts.
About Alkermes
Alkermes plc is a biopharmaceutical company headquartered in Dublin, Ireland. It focuses on developing and commercializing treatments for unmet medical needs in areas like opioid and alcohol dependence, schizophrenia, and bipolar disorder. The company markets products such as ARISTADA and VIVITROL and collaborates with companies like Janssen Pharmaceutica.
Bottom Line
Alkermes plc continues to attract positive analyst attention, with Needham reiterating its buy rating and setting a $54 price target. Investors keep an eye on this biopharma firm for its innovative treatments and strong market presence. It's important to note that analyst ratings are based on past data and may not reflect the current market conditions.
Get Alkermes plc alerts
New 13F filings, insider trades, and analyst moves on $ALKS, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.